Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
Cell-Based Immune Therapy Shows Promise in Leukemia Patients
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Cancer Care; Clinical Trials; Cell Engineering; Experimental Therapeutics; Leukemias; Research
100 comments
Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
Launch of Stem Cell Therapy Trial Offers Hope for Patients with Inherited Blood Disorder
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Cancer Care; Clinical Trials; Cell Engineering; Cell Therapy; Research
20 comments
Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
Cell-Based Therapies Show Promise
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.

Cell Engineering; Cell Therapy; Immunotherapy; Drug Discovery; Experimental Therapeutics; Research
14 comments

Featured Blog Posts

Large Genetic Study Could Improve Endometrial Cancer Diagnosis and Treatment
A Single Early PSA Test Found to Predict Long-Term Risk of Aggressive Prostate Cancer
Memorial Sloan-Kettering Experts Discuss Awake Surgery for Brain Tumors

Center News

Pictured: Center News, April 2013
Read Our Magazine »

Subscribe to Our E-newsletter

Get the latest information about cancer care.